Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Volume 45 Issue 3, March 2013

Editorial

  • Cancer genomes are now rapidly yielding to analysis, showing the heterogeneity of the mutational events and processes contributing to disease. This diversity is enormous and occurs at many levels. Consequently, the first clues from exome sequencing will increasingly need to be complemented by integrated analyses and extended to implicate mutations relevant to treatment outcomes.

    Editorial

    Advertisement

Top of page ⤴

News & Views

  • A new study in mice shows that, during meiosis, the decision to mature a double-strand break into a crossover is controlled by a dosage-sensitive regulator, RNF212. This finding provides insight into the crossover maturation process and may help explain how sequence polymorphisms in RNF212 alter the frequency of crossing over in humans.

    • Cathleen M Lake
    • R Scott Hawley
    News & Views
  • A recent study shows that the life history of chronic lymphocytic leukemia is characterized by a complex and dynamic architecture involving the development of subclones with changing dominance over time. This innovative study provides a framework to design anticipation-based chemotherapy approaches for cancer treatment.

    • Xose S Puente
    • Carlos López-Otín
    News & Views
  • Two new loci for premature fusion of the cranial sutures in humans suggest a common endpoint in osteoblast regulation, linking upregulation of phosphorylated ERK1/2 and TWIST1 haploinsufficiency.

    • David R FitzPatrick
    News & Views
Top of page ⤴

Research Highlights

Top of page ⤴

Perspective

  • Jake Gratten and colleagues discuss challenges in interpreting the role of de novo mutations in neuropsychiatric and other complex diseases. They argue that the burden of proof for causality for a single de novo mutation must be set high and that curation of de novo mutations and their associated phenotypes in databases will be critical for the robust interpretation of exome sequencing studies.

    • Jacob Gratten
    • Peter M Visscher
    • Naomi R Wray
    Perspective
Top of page ⤴

Brief Communication

Top of page ⤴

Article

Top of page ⤴

Letter

Top of page ⤴

Search

Quick links